Garland Surgical closes €3.5M seed to push TriActiv Hip toward clinic
What's the deal? UK-based orthopaedic device company Garland SurgicalDealroom has a profile for this one. Try Dealroom → has closed a €3.5 million seed round to advance its patented TriActiv Hip system toward commercialisation. The round includes €2.1 million in equity financing and up to €1.4 million in non-dilutive grant funding from Malta EnterpriseDealroom has a profile for this one. Try Dealroom →.
The money will fund product development, regulatory preparation, and early clinical activities. Founded in 2022 and headquartered near Worcester, the company has operations in Malta and collaborations across Europe.
The TriActiv Hip — evolved from the University of Malta-backed MaltaHip project led by co-founder and chief executive officer Simon Mifsud — is a triaxial hip system designed to offer a wider, more natural range of motion than traditional ball-and-socket implants, while improving stability and reducing wear.
Why now? Garland is using the seed close as a springboard for a larger Series A, which it is preparing with Ferghana Partners, a life sciences investment bank with offices in New York, California, and London. That financing would fund clinical studies, FDA and EU MDR regulatory submissions, and eventual market entry.
The company said its Series A will likely come in two tranches: the first for regulatory clearance, the second for clinical trials and commercialisation.
What could go wrong? Medtech is a long, capital-intensive road. Garland still needs to complete final design verification, build out quality and regulatory infrastructure, and run first-in-human clinical trials — all before it can sell a single implant. Regulatory approval in both the US and EU adds complexity and cost.
Competition is fierce. Established orthopaedic players like Zimmer BiometDealroom has a profile for this one. Try Dealroom → and Smith+Nephew dominate the hip replacement market, and convincing surgeons to adopt a fundamentally different implant design is no small task.
The signal: Garland Surgical's seed round underscores a growing appetite for early-stage medtech bets targeting the ageing population, even as the sector's long development timelines typically deter pre-revenue investors. The involvement of Malta Enterprise — a government and non-profit investor — alongside corporate backer Kernaghan & Partners points to a blended funding model that lets hardware-heavy startups stretch runway without excessive dilution, a playbook likely to become more common as EU MDR compliance costs continue to climb.
Read more: whoswho.mt
